Russia, CIS OTC Deal Between J&J, JB Chem Appears To Be Unraveling
This article was originally published in PharmAsia News
An over-the-counter drug deal between India's JB Chem and U.S. drug maker Johnson & Johnson to sell products in Russia and the Commonwealth of Independent States appears to be unraveling.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.